Showing 1 - 15 results of 15 for search 'Danushka K. Wijesundara', query time: 0.06s Refine Results
  1. 1
    Use and Misuse of Statistical Significance in Survival Analyses

    Use and Misuse of Statistical Significance in Survival Analyses by Yoichi Furuya, Danushka K. Wijesundara, Teresa Neeman, Dennis W. Metzger

    Published 2014-05-01
    Get full text
    Article
  2. 2
    Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity

    Impact of Pre-Existing Immunity to Influenza on Live-Attenuated Influenza Vaccine (LAIV) Immunogenicity by Sreeja Roy, Clare M. Williams, Danushka K. Wijesundara, Yoichi Furuya

    Published 2020-11-01
    Get full text
    Article
  3. 3
    Reduced interleukin-4 receptor α expression on CD8+ T cells correlates with higher quality anti-viral immunity.

    Reduced interleukin-4 receptor α expression on CD8+ T cells correlates with higher quality anti-viral immunity. by Danushka K Wijesundara, David C Tscharke, Ronald J Jackson, Charani Ranasinghe

    Published 2013-01-01
    Get full text
    Article
  4. 4
    Fear of Influenza Resurgence amid COVID-19 Pandemic: Need for Effective Flu Vaccine Still Exists

    Fear of Influenza Resurgence amid COVID-19 Pandemic: Need for Effective Flu Vaccine Still Exists by Danushka K. Wijesundara, Clare Williams, Wei Sun, Andrea Marias Furuya, Yoichi Furuya

    Published 2021-10-01
    Get full text
    Article
  5. 5
    Immunological Memory in Imiquimod-Induced Murine Model of Psoriasiform Dermatitis

    Immunological Memory in Imiquimod-Induced Murine Model of Psoriasiform Dermatitis by Kevin Fenix, Danushka K. Wijesundara, Allison J. Cowin, Branka Grubor-Bauk, Zlatko Kopecki

    Published 2020-09-01
    Get full text
    Article
  6. 6
    Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C

    Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C by Makutiro Ghislain Masavuli, Danushka K. Wijesundara, Joseph Torresi, Eric J. Gowans, Branka Grubor-Bauk

    Published 2017-12-01
    Get full text
    Article
  7. 7
    Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines

    Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines by Ashish C. Shrestha, Danushka K. Wijesundara, Makutiro G. Masavuli, Zelalem A. Mekonnen, Eric J. Gowans, Branka Grubor-Bauk

    Published 2019-04-01
    Get full text
    Article
  8. 8
    Use of an in vivo FTA assay to assess the magnitude, functional avidity and epitope variant cross-reactivity of T cell responses following HIV-1 recombinant poxvirus vaccination.

    Use of an in vivo FTA assay to assess the magnitude, functional avidity and epitope variant cross-reactivity of T cell responses following HIV-1 recombinant poxvirus vaccination. by Danushka K Wijesundara, Charani Ranasinghe, Ronald J Jackson, Brett A Lidbury, Christopher R Parish, Benjamin J C Quah

    Published 2014-01-01
    Get full text
    Article
  9. 9
    Rapid Response Subunit Vaccine Design in the Absence of Structural Information

    Rapid Response Subunit Vaccine Design in the Absence of Structural Information by Danushka K. Wijesundara, Danushka K. Wijesundara, Michael S. Avumegah, Michael S. Avumegah, Julia Lackenby, Julia Lackenby, Naphak Modhiran, Naphak Modhiran, Ariel Isaacs, Paul R. Young, Paul R. Young, Paul R. Young, Daniel Watterson, Daniel Watterson, Daniel Watterson, Keith J. Chappell, Keith J. Chappell, Keith J. Chappell

    Published 2020-11-01
    Get full text
    Article
  10. 10
    Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus

    Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus by Jason Gummow, Makutiro G. Masavuli, Zelalem A. Mekonnen, Yanrui Li, Danushka K. Wijesundara, Ashish C. Shrestha, Ilia Voskoboinik, Eric J. Gowans, Branka Grubor-Bauk

    Published 2020-01-01
    Get full text
    Article
  11. 11
    Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner

    Cytolytic DNA vaccine encoding lytic perforin augments the maturation of- and antigen presentation by- dendritic cells in a time-dependent manner by Danushka K. Wijesundara, Wenbo Yu, Ben J. C. Quah, Preethi Eldi, John D. Hayball, Kerrilyn R. Diener, Ilia Voskoboinik, Eric J. Gowans, Branka Grubor-Bauk

    Published 2017-08-01
    Get full text
    Article
  12. 12
    Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection

    Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection by Zelalem A. Mekonnen, Branka Grubor-Bauk, Makutiro G. Masavuli, Ashish C. Shrestha, Charani Ranasinghe, Rowena A. Bull, Andrew R. Lloyd, Eric J. Gowans, Danushka K. Wijesundara

    Published 2019-04-01
    Get full text
    Article
  13. 13
    Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines

    Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines by Ariel Isaacs, Zheyi Li, Stacey T. M. Cheung, Danushka K. Wijesundara, Christopher L. D. McMillan, Naphak Modhiran, Paul R. Young, Charani Ranasinghe, Daniel Watterson, Keith J. Chappell

    Published 2021-01-01
    Get full text
    Article
  14. 14
    Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine

    Superior efficacy of a skin-applied microprojection device for delivering a novel Zika DNA vaccine by Danushka K. Wijesundara, Arthur Yeow, Christopher L.D. McMillan, Jovin J.Y. Choo, Aleksandra Todorovic, Zelalem A. Mekonnen, Makutiro G. Masavuli, Paul R. Young, Eric J. Gowans, Branka Grubor-Bauk, David A. Muller

    Published 2023-12-01
    Get full text
    Article
  15. 15
    Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialResearch in context

    Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18–55 years or ≥56 years: 12-month results from a randomise... by Keith J. Chappell, Francesca L. Mordant, Alberto A. Amarilla, Naphak Modhiran, Benjamin Liang, Zheyi Li, Danushka K. Wijesundara, Julia A. Lackenby, Paul Griffin, Jillian K. Bennet, Luca Hensen, Wuji Zhang, Thi H.O. Nguyen, Mai H. Tran, Peter Tapley, James Barnes, Patrick C. Reading, Katherine Kedzierska, Charani Ranasinghe, Kanta Subbarao, Daniel Watterson, Paul R. Young, Trent P. Munro

    Published 2023-11-01
    Get full text
    Article

Search Tools: